Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study-Reference-Cited by-同舟云学术

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Published:2017-06 Issue:2 Volume:16 Page:e73-e88
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Cheng Ann-Lii,Cornelio Gerardo,Shen Lin,Price Timothy,Yang Tsai-Sheng,Chung Ik Joo,Dai Guang-Hai,Lin Jen-Kou,Sharma Atul,Yeh Kun-Huei,Ma Brigette,Zaatar Adel,Guan Zhongzhen,Masood Nehal,Srimuninnimit Vichien,Yau Thomas,Gibbs Peter,Wang Xiuwen,Doval Dinesh Chandra,Oh Seung-Taek,Shim Byoung Yong,Gorospe Charity,Wang Hwei-Ming,Sirachainan Ekaphop,Hill Andrew,Suh Kwang Wook,Beier Frank,Chatterjee Sudipto,Lim Robert

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference26 articles.

1. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study;Bokemeyer;Ann Oncol,2011

2. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer;Bokemeyer;Eur J Cancer,2015

3. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

4. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status;Van Cutsem;J Clin Oncol,2011

5. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer;Van Cutsem;J Clin Oncol,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. Cetuximab every 2 weeks versus standard weekly dosing administration schedule;Future Oncology;2023-10-18

3. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm;Clinical Pharmacology & Therapeutics;2023-05-11

4. Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer;Future Oncology;2023-05

5. Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study;Asia-Pacific Journal of Clinical Oncology;2023-02-28